SCHEMBL4848155

SCHEMBL4848155

COc1cc(COc2nc(-c3ccccc3)ncc2C(=O)O)ccc1OCc1nc(-c2ccco2)oc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.52
MAPT P10636 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
TSHR P16473 3/20 0.47
HSD17B10 Q99714 3/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.47
ADORA3 P0DMS8 6/20 0.44
ADORA2A P29274 6/20 0.44
ADORA1 P30542 6/20 0.44
PPARA Q07869 1/20 0.44
LMNA P02545 2/20 0.42
ALOX15 P16050 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
FFAR1 O14842 1/20 0.40
ADORA2B P29275 2/20 0.39
XDH P47989 1/20 0.39
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852701 0.93 PPARG (0.49) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4850970 0.89 PPARG (0.50) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4848159 0.89 PPARG (0.51) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4845725 0.86 PPARG (0.48) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4845809 0.86 PPARG (0.48) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4848830 0.86 PPARG (0.48) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4851669 0.82 PPARG (0.51) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4854552 0.82 PPARG (0.51) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4850543 0.81 PPARG (0.61) PPARGMAPTSMN1; SMN2TSHRHSD17B10
SCHEMBL4852628 0.81 PPARG (0.56) PPARGMAPTSMN1; SMN2TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885MAPT 4700/4885SMN1; SMN2 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.